The relationship between the combined use of various proton pump inhibitors with antiplatelet drugs and the risk of cardiovascular complications


Cite item

Full Text

Abstract

In the article the problem of the combined use of clopidogrel and various proton pump inhibitors (PPIs) in terms of cardiovascular complications risk and stent thrombosis is considered. The results of meta - analyses and a systematic reviews affecting this issue are represented in detail. The inter - drug interactions mechanisms of various PPIs with clopidogrel based on the characteristics of the metabolism in the liver cytochromes system are discussed. The authors conducted a search, systematization and analysis of studies regarding the association between cardiovascular risk and combined use of individual medications from PPI class with clopidogrel, and these results are presented in the review. Currently available data do not allow to answer the question about the differences between individual PPIs in their impact on the risk of adverse cardiovascular events due to the small number of such studies, design heterogeneity, differences in the inclusion criteria and end points as well as in the rate of administration of individual PPIs.

About the authors

O D Ostroumova

Pirogov Russian National Research Medical University - Russian Clinical and Research Center of Gerontology; Sechenov First Moscow State Medical University (Sechenov University)

Email: ostroumova.olga@mail.ru
д.м.н., проф., зав. лаб. клинической фармакологии и фармакотерапии ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» - ОСП «Российский геронтологический научно-клинический центр»; проф. каф. клинической фармакологии и пропедевтики внутренних болезней ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»; ORCID: 0000-0002-0795-8225 Moscow, Russia

A I Kochetkov

Pirogov Russian National Research Medical University - Russian Clinical and Research Center of Gerontology

к.м.н., н.с. лаб. клинической фармакологии и фармакотерапии ФГБОУ ВО «РНИМУ им. Н. И. Пирогова» - ОСП «Российский геронтологический научно-клинический центр»; ORCID: 0000-0001-5801-3742 Moscow, Russia

A P Pereverzev

Pirogov Russian National Research Medical University - Russian Clinical and Research Center of Gerontology

к.м.н., н.с. лаб. клинической фармакологии и фармакотерапии ФГБОУ ВО «РНИМУ им. Н. И. Пирогова» - ОСП «Российский геронтологический научно-клинический центр»; ORCID: 0000-0001-7168-3636 Moscow, Russia

E V Kravchenko

Yevdokimov Moscow State University of Medicine and Dentistry

студент 4-го курса лечебного факультета ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»; ORCID: 0000-0001-8551-1421 Moscow, Russia

A N Kazjulin

Yevdokimov Moscow State University of Medicine and Dentistry

проф., д.м.н., проф. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова» Moscow, Russia

D N Andreev

Yevdokimov Moscow State University of Medicine and Dentistry

к.м.н., доц. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова» Moscow, Russia

E E Pavleeva

Yevdokimov Moscow State University of Medicine and Dentistry

к.м.н., ассистент каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова» Moscow, Russia

References

  1. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296
  2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-77. doi: 10.1093/eurheartj/ehx393
  3. Roffi M, Patrono C, Collet J.P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320
  4. Valgimigli M, Bueno H, Byrne R.A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-60. doi: 10.1093/eurheartj/ehx419
  5. Neumann F.J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394
  6. Levine G.N, Bates E.R, Bittl J.A, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115. doi: 10.1016/j.jacc.2016.03.513
  7. Gutermann I.K, Niggemeier V, Zimmerli L.U, et al. Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines. Medicine (Baltimore). 2015 Jan;94(1):e377. doi: 10.1097/MD.0000000000000377
  8. Diener H.C. Preventing major gastrointestinal bleeding in elderly patients. Lancet. 2017 Jul 29;390(10093):435-7. doi: 10.1016/S0140-6736(17)31507-6
  9. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non - valvular atrial fibrillation. Europace. 2013 May;15(5):625-51. doi: 10.1093/europace/eut083
  10. Yu L.Y, Sun L.N, Zhang X.H, Li Y.Q, Yu L, Yuan Z.Q, Meng L, Zhang H.W, Wang Y.Q. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. Adv Ther. 2017;34(5):1070-86. doi: 10.1007/s12325-017-0532-9
  11. Gilard M, Arnaud B, Cornily J.C, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall J.F, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double - blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-60. doi: 10.1016/j.jacc.2007.06.064
  12. Small D.S, Farid N.A, Payne C.D, Weerakkody G.J, Li Y.G, Brandt J.T, Salazar D.E, Winters K.J. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48:475-84. doi: 10.1177/0091270008315310
  13. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A, von Beckerath N. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714-9.
  14. O’Donoghue M.L, Braunwald E, Antman E.M, Murphy S.A, Bates E.R, Rozenman Y, Michelson A.D, Hautvast R.W, Ver Lee P.N, Close S.L, Shen L, Mega J.L, Sabatine M.S, Wiviott S.D. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton - pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-97. doi: 10.1016/S0140-6736(09)61525-7
  15. U.S. Food and Drug Administration. Public Health Advisory: Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). 11 17, 2009 [Archived Content]. Available at: http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm190825.htm (Accessed November 26, 2013).
  16. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton pump inhibitors. 5 29, 2009 Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000194.jsp&mid=WC0b01ac058004d5c1 (Accessed November 26, 2013).
  17. Ho P.M, Maddox T.M, Wang L, Fihn S.D, Jesse R.L, Peterson E.D, Rumsfeld J.S. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-44. doi: 10.1001/jama.2009.261
  18. Juurlink D.N, Gomes T, Ko D.T, Szmitko P.E, Austin P.C, Tu J.V, Henry D.A, Kopp A, Mamdani M.M. A population - based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-8. doi: 10.1503/cmaj.082001
  19. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg P.G, Ferrières J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-75. doi: 10.1056/NEJMoa0808227
  20. Hu W, Tong J, Kuang X, Chen W, Liu Z. Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta - analysis. Medicine (Baltimore). 2018 Jan;97(3):e9638. doi: 10.1097/MD.0000000000009638
  21. Melloni С, Washam J.B, Jones W.S, Halim S, Hasselblad V, Mayer S.B, Heidenfelder B.L. Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy: A Systematic Review. Circ Cardiovasc Qual Outcomes. 2015;8(1):47-55. doi: 10.1161/CIRCOUTCOMES. 114.001177
  22. Sherwood M.W, Melloni C, Jones W.S, Washam J.B, Hasselblad V, Dolor R.J. Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. J Am Heart Assoc. 2015 Oct 29;4(11). pii: e002245. doi: 10.1161/JAHA.115.002245
  23. Charlot M, Ahlehoff O, Norgaard M.L, Jørgensen C.H, Sørensen R, Abildstrøm S.Z, Hansen P.R, Madsen J.K, Køber L, Torp-Pedersen C, Gislason G. Proton - pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378-86. doi: 10.7326/0003-4819-153-6-201009210-00005
  24. Kreutz R.P, Stanek E.J, Aubert R, Yao J, Breall J.A, Desta Z, Skaar T.C, Teagarden J.R, Frueh F.W, Epstein R.S, Flockhart D.A. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy. 2010;30(8):787-96. doi: 10.1592/phco.30.8.787
  25. Ray W.A, Murray K.T, Griffin M.R, Chung C.P, Smalley W.E, Hall K, Daugherty J.R, Kaltenbach L.A, Stein C.M. Outcomes with concurrent use of clopidogrel and proton - pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337-45. doi: 10.7326/0003-4819-152-6-201003160-00003
  26. Simon T, Steg P.G, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, Drouet E, Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123(5):474-82. doi: 10.1161/CIRCULATIONAHA.110.965640
  27. Van Boxel O.S, van Oijen M.G, Hagenaars M.P, Smout A.J, Siersema P.D. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol. 2010 Nov;105(11):2430-6; quiz 2437. doi: 10.1038/ajg.2010.334
  28. https://www.drugbank.ca
  29. Scott S.A, Sangkuhl K, Stein C.M, Hulot J.S, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23.
  30. Royal Dutch Pharmacists Association (KNMP). Dutch Pharmacogenetics Working Group (DPWG). Pharmacogenetic Guidelines [Internet]. Netherlands. Clopidogrel - CYP2C19 [Cited July 2017]. Available at: http://kennisbank.knmp.nl [Access is restricted to KNMP membership].
  31. https://www.accessdata.fda.gov/
  32. Goodman S.G, Clare R, Pieper K.S, Nicolau J.C, Storey R.F, Cantor W.J, Mahaffey K.W, Angiolillo D.J, Husted S, Cannon C.P, James S.K, Kilhamn J, Steg P.G, Harrington R.A, Wallentin L; Platelet Inhibition and Patient Outcomes Trial Investigators. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012 Feb 28;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912
  33. Bhatt D.L, Cryer B.L, Contant C.F, Cohen M, Lanas A, Schnitzer T.J, Shook T.L, Lapuerta P, Goldsmith M.A, Laine L, Scirica B.M, Murphy S.A, Cannon C.P; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11;363(20):1909-17. doi: 10.1056/NEJMoa1007964
  34. Zairis M.N, Tsiaousis G.Z, Patsourakos N.G, Georgilas A.T, Kontos C.F, Adamopoulou E.N, Vogiatzidis K, Argyrakis S.K, Fakiolas C.N, Foussas S.G. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 2010 Feb;26(2):e54-7. doi: 10.1016/S0828-282X(10)70008-8
  35. Rossini R, Capodanno D, Musumeci G, Lettieri C, Lortkipanidze N, Romano M, Nijaradze T, Tarantini G, Cicorella N, Sirbu V, Guagliumi G, Rosiello R, Valsecchi O, Gavazzi A. Safety of clopidogrel and proton pump inhibitors in patients undergoing drug - eluting stent implantation. Coron Artery Dis. 2011 May;22(3):199-205. doi: 10.1097/MCA.0b013e328343b03a
  36. Vaduganathan M, Bhatt D.L, Cryer B.L, Liu Y, Hsieh W.H, Doros G, Cohen M, Lanas A, Schnitzer T.J, Shook T.L, Lapuerta P, Goldsmith M.A, Laine L, Cannon CP; COGENT Investigators Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016 Apr 12;67(14):1661-71. doi: 10.1016/j.jacc.2015.12.068
  37. Macaione F, Montaina C, Evola S, Novo G, Novo S. Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug - eluting stent implantation. ISRN Cardiol. 2012;2012:692761. doi: 10.5402/2012/692761
  38. Wei P, Zhang Y.G, Ling L, Tao Z.Q, Ji L.Y, Bai J, Zong B, Jiang C.Y, Zhang Q, Fu Q, Yang X.J.Effects of the short - term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med. 2016;12(5):2861-4. doi: 10.3892/etm.2016.3693
  39. Zhang J.R, Wang D.Q, Du J, Qu G.S, Du J.L, Deng S.B, Liu Y.J, Cai J.X, She Q. Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial. Medicine (Baltimore). 2015 Dec;94(50):e2262. doi: 10.1097/MD.0000000000002262
  40. Gargiulo G, Costa F, Ariotti S, Biscaglia S, Campo G, Esposito G, Leonardi S, Vranckx P, Windecker S, Valgimigli M. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual - antiplatelet therapy duration: Insights from the PROlonging Dual - antiplatelet treatment after Grading stent - induced Intimal hyperplasia studY trial. Am Heart J. 2016 Apr;174:95-102. doi: 10.1016/j.ahj.2016.01.015
  41. Burkard T, Kaiser C.A, Brunner-La Rocca H, Osswald S, Pfisterer M.E, Jeger R.V; BASKET Investigators. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. J Intern Med. 2012 Mar;271(3):257-63. doi: 10.1111/j.1365-2796.2011.02423.x
  42. Yasu T, Ikee R, Miyasaka Y, Chubachi H, Saito S. Efficacy and safety of concomitant use of rabeprazole during dual - antiplatelet therapy with clopidogrel and aspirin after drug - eluting stent implantation: a retrospective cohort study. Yakugaku Zasshi. 2010 Dec;130(12):1743-50. doi: 10.1248/yakushi.130.1743
  43. James S, Akerblom A, Cannon C.P, Emanuelsson H, Husted S, Katus H, Skene A, Steg P.G, Storey R.F, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003
  44. Kaiser C, Brunner-La Rocca H.P, Buser P.T, Bonetti P.O, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer M.E; BASKET Investigators. Incremental cost - effectiveness of drug - eluting stents compared with a third - generation bare - metal stent in a real - world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet. 2005;366(9489):921-9. doi: 10.1016/S0140-6736(05)67221-2

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies